LONDON – Nanobiotix SA has won European marketing approval for NBTXR-3, a first-in-class nanoparticle device that boosts the effectiveness of standard radiotherapy in killing cancer cells. The product, now christened Hensify, is a nanoparticle formulation of hafnium oxide, a material that absorbs X-rays, increasing the effective dose of radiation in a tumor. It is administered as a one-time injection into a tumor, given the day before conventional radiotherapy treatment.